Fibrogen and hifibio announce transformative partnership to advance next-generation therapies for patients with cancer and autoimmune disease

San francisco and cambridge, mass., june 17, 2021 (globe newswire) -- fibrogen, inc. (nasdaq: fgen) and hifibio therapeutics, a private, multinational clinical-stage biotherapeutics company with expertise in immune modulation and single cell science announced a partnership covering three hifibio programs.
FGEN Ratings Summary
FGEN Quant Ranking